Perceptive Advisors’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

Perceptive Advisors’s Portfolio OTLKW Stock Details OTLKW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-420,875	Closed	-$93K	–	170
2020 Q4	$93K	Hold	420,875	–	–	﹤0.01%	139
2020 Q3	$54K	Hold	420,875	–	–	﹤0.01%	126
2020 Q2	$108K	Hold	420,875	–	–	﹤0.01%	125
2020 Q1	$46K	Hold	420,875	–	–	﹤0.01%	112
2019 Q4	$33K	Hold	420,875	–	–	﹤0.01%	112
2019 Q3	$48K	Hold	420,875	–	–	﹤0.01%	109
2019 Q2	$46K	Hold	420,875	–	–	﹤0.01%	103
2019 Q1	$159K	Hold	420,875	–	–	﹤0.01%	98
2018 Q4	$72K	Buy	+420,875	New	+$53.1K	﹤0.01%	99

Other funds holding OTLKW

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

CIA

Compass Ion Advisors Conshohocken, Pennsylvania $1.05B AUM 16.28% 1-Year Est. Return

Perceptive Advisors's OTLKW Position: Q1 2021 in Review

Perceptive Advisors sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q1 2021, closing a stake of 420,875 shares — an estimated $93K sold.

Perceptive Advisors first reported a position in OTLKW in Q4 2018 and held it in 9 quarters. The position peaked at $159K in Q1 2019. 4 funds tracked by Wall St. Rank hold OTLKW as of Q1 2021.

Perceptive Advisors reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q1 2021 after selling out during the quarter.
Perceptive Advisors sold 420,875 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q1 2021, an estimated $93K.
Perceptive Advisors first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q4 2018 and held it in 9 quarters.
Perceptive Advisors's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $159K in Q1 2019.
4 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q1 2021.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.